Mibolerone
| Clinical data | |
|---|---|
| Trade names | Cheque Drops, Matenon | 
| Other names | U-10997; CDB-904; Dimethylnandrolone; Dimethylnortestosterone; DMNT; 7α,17α-Dimethyl-19-nortestosterone; 7α,17α-Dimethylestr-4-en-17β-ol-3-one | 
| AHFS/Drugs.com | International Drug Names | 
| Routes of administration  | By mouth | 
| Drug class | Androgen; Anabolic steroid; Progestogen | 
| ATC code | 
  | 
| Legal status | |
| Legal status | 
  | 
| Pharmacokinetic data | |
| Metabolism | Liver | 
| Identifiers | |
  | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.020.951 | 
| Chemical and physical data | |
| Formula | C20H30O2 | 
| Molar mass | 302.458 g·mol−1 | 
| 3D model (JSmol) | |
  | |
  | |
| (verify) | |
Mibolerone, also known as dimethylnortestosterone (DMNT) and sold under the brand names Cheque Drops and Matenon, is a synthetic, orally active, and extremely potent anabolic–androgenic steroid (AAS) and a 17α-alkylated nandrolone (19-nortestosterone) derivative which was marketed by Upjohn for use as a veterinary drug. It was indicated specifically as an oral treatment for prevention of estrus (heat) in adult female dogs.